Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.47 |
| ▸ | ACACA | Q13085 | 13/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spirotetramat SCHEMBL27350845 | 0.91 | ACACB (0.49) | ACACBACACAMEN1KMT2ASMN1; SMN2 | |
| Spirotetramat SCHEMBL12022413 | 0.91 | ACACB (0.49) | ACACBACACAMEN1KMT2ASMN1; SMN2 | |
| Spirotetramat SCHEMBL337030 | 0.91 | ACACB (0.49) | ACACBACACAMEN1KMT2ASMN1; SMN2 | |
| Spirotetramat SCHEMBL14855635 | 0.91 | ACACB (0.49) | ACACBACACAMEN1KMT2ASMN1; SMN2 | |
| Spirotetramat SCHEMBL26389 | 0.91 | ACACB (0.49) | ACACBACACAMEN1KMT2ASMN1; SMN2 | |
| Spirotetramat SCHEMBL2584908 | 0.90 | ACACB (0.49) | ACACBACACAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12778773 | 0.89 | ACACB (0.47) | ACACBACACAGABRA1GABRB2BACE1 | |
| SCHEMBL12564504 | 0.85 | ACACB (0.57) | ACACBACACABACE1 | |
| SCHEMBL2850592 | 0.85 | ACACB (0.52) | ACACBACACAMEN1KMT2A | |
| SCHEMBL6371037 | 0.84 | ACACB (0.48) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056853-B2 | N-Thio-anthranilamid compounds and their use as pesticides | BASF SE (DE) | 2015-06-16 | — | — | US | disclosed |
| US-20140378458-A1 | N-Thio-anthranilamid compounds and their use as pesticides | BASF SE (DE) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378458-A1 | N-Thio-anthranilamid compounds and their use as pesticides | NAT1, AAAS, ACHE | ACACB 632/4885ACACA 79/4885GABRA1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.